Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.61 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.61 |
| ▸ | COMT | P21964 | 1/20 | 0.50 |
| ▸ | SYK | P43405 | 2/20 | 0.47 |
| ▸ | DHODH | Q02127 | 1/20 | 0.46 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.43 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.41 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.41 |
| ▸ | VHL | P40337 | 1/20 | 0.41 |
| ▸ | PIP4K2A | P48426 | 1/20 | 0.40 |
| ▸ | PIP4K2C | Q8TBX8 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17517233 | 0.89 | MKNK1 (0.51) | MKNK1MKNK2COMTSYKDHODH | |
| SCHEMBL15730173 | 0.85 | MKNK1 (0.59) | MKNK1MKNK2DHODHPTGS1PTGS2 | |
| SCHEMBL2757253 | 0.85 | MKNK1 (0.59) | MKNK1MKNK2DHODHPTGS1PTGS2 | |
| SCHEMBL30563610 | 0.84 | MKNK1 (0.58) | MKNK1MKNK2DHODHPTGS1PTGS2 | |
| SCHEMBL2084918 | 0.84 | MKNK1 (0.58) | MKNK1MKNK2DHODHPTGS1PTGS2 | |
| SCHEMBL12947927 | 0.83 | DHODH (0.48) | MKNK1MKNK2COMTSYKDHODH | |
| SCHEMBL12988895 | 0.83 | MKNK1 (0.62) | MKNK1MKNK2COMTDHODHPTGS1 | |
| SCHEMBL13368032 | 0.83 | MKNK1 (0.62) | MKNK1MKNK2DHODHPTGS1PTGS2 | |
| SCHEMBL20371666 | 0.83 | MKNK1 (0.57) | MKNK1MKNK2DHODHPTGS1PTGS2 | |
| SCHEMBL18162732 | 0.83 | MKNK1 (0.57) | MKNK1MKNK2COMTDHODHPTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11193065-B2 | Liquid crystal composition, method of producing the same, and retardation film constituted from the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2021-12-07 | — | — | US | disclosed |
| US-20200165519-A1 | POLYMERIZABLE LIQUID CRYSTAL COMPOSITION AND RETARDATION PLATE | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2020-05-28 | — | — | US | disclosed |
| WO-2020085319-A1 | CYCLIC AZINE COMPOUND, MATERIAL FOR ORGANIC ELECTROLUMINESCENT ELEMENTS, ELECTRON TRANSPORT MATERIAL FOR ORGANIC ELECTROLUMINESCENT ELEMENTS, AND ORGANIC ELECTROLUMINESCENT ELEMENT | 東ソー株式会社 | 2020-04-30 | — | — | WO | disclosed |
| US-20190276744-A1 | LIQUID CRYSTAL COMPOSITION | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2019-09-12 | — | — | US | disclosed |
| US-10407619-B2 | Liquid crystal composition | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2019-09-10 | — | — | US | disclosed |
| EP-3224258-B1 | 4,5,6,7-TETRAHYDRO-1H-PYRAZOLO[4,3-C]PYRIDIN-3-AMINE COMPOUNDS AS CBP AND/OR EP300 INHIBITORS | GENENTECH INC (US) | 2019-08-14 | — | — | EP | disclosed |
| US-10336938-B2 | Liquid crystal composition | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2019-07-02 | — | — | US | disclosed |
| EP-3323821-A1 | HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS | Pfizer Inc (US) | 2018-05-23 | — | — | EP | disclosed |
| US-20170335191-A1 | LIQUID CRYSTAL COMPOSITION | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2017-11-23 | — | — | US | disclosed |
| US-20170335191-A1 | LIQUID CRYSTAL COMPOSITION | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2017-11-23 | — | — | US | disclosed |
| US-20170145312-A1 | LIQUID CRYSTAL COMPOSITION | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2017-05-25 | — | — | US | disclosed |
| US-20170145312-A1 | LIQUID CRYSTAL COMPOSITION | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2017-05-25 | — | — | US | disclosed |
| US-20170137405-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | GILEAD SCIENCES, INC. | 2017-05-18 | — | — | US | disclosed |
| US-9540343-B2 | Compounds for the treatment of HIV | GILEAD SCIENCES, INC. (US) | 2017-01-10 | — | — | US | disclosed |
| WO-2016086200-A9 | 4,5,6,7-TETRAHYDRO-1 H-PYRAZOLO[4,3-C]PYRIDIN-3-AMINE COMPOUNDS AS CBP AND/OR EP300 INHIBITORS | GENENTECH, INC. (US) | 2016-06-23 | — | — | WO | disclosed |
| US-20160158207-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2016-06-09 | — | — | US | disclosed |
| WO-2016086200-A1 | 4,5,6,7-TETRAHYDRO-1 H-PYRAZOLO[4,3-C]PYRIDIN-3-AMINE COMPOUNDS AS CBP AND/OR EP300 INHIBITORS | GENENTECH, INC. (US) | 2016-06-02 | — | — | WO | disclosed |
| EP-2395002-B1 | PHARMACEUTICAL COMPOSITION CONTAINING A HETEROCYCLIC MODULATOR OF ATP-BINDING CASSETTE TRANSPORTERS. | VERTEX PHARMA (US) | 2014-06-18 | — | — | EP | disclosed |
| US-20140142085-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | GILEAD SCIENCES, INC. (US) | 2014-05-22 | — | — | US | disclosed |
| US-6362009-B1 | CAPTURING A SUBSTRATE ON SOLID SUPPORT AND ACTIVATINGSUBSTRATE TO REACT WITH REAGENT WITH WHICH UNACTIVATED SUBSTRATE DOES NOT REACT; REACTING ACTIVATED SUBSTRATE ON SOLID PHASE WITH REAGENT TO GIVE AN ADDITION PRODUCT | MERCK & CO., INC. | 2002-03-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170335191-A1 | LIQUID CRYSTAL COMPOSITION | RCC1, CCDC47, ACIN1 | MKNK1 2362/4885MKNK2 2558/4885COMT 3466/4885 |
| US-20160158207-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | EP300, HDAC1, HDAC10 | MKNK1 2377/4885MKNK2 1286/4885COMT 4037/4885 |
| US-20170137405-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | CCR5, NPC1, FURIN | MKNK1 2159/4885MKNK2 2342/4885COMT 865/4885 |
| US-20140142085-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | CCR5, NPC1, FURIN | MKNK1 2159/4885MKNK2 2342/4885COMT 865/4885 |
| US-10407619-B2 | Liquid crystal composition | RCC1, CCDC47, ACIN1 | MKNK1 2362/4885MKNK2 2558/4885COMT 3466/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.